Replies to post #208274 on Biotech Values

[CT]

So the analyst who wrote this "report" (ahem) receives compensation based on the volume of trading in this security at his firm. Glad I skipped right to the appendix as usual.

[RockRat]

TGTX: thanks. Points to some of the competition, but not all (doesn't even mention CAR-T players, for example), and uses a pretty soft discount rate considering the rapidly evolving treatment paradigms in the targeted indications. The effect on t-cells/cMyc has been known to anyone paying attention to their conference presentations; nothing new there.

I think a six or seven bagger in a year is pretty implausible, but two or three perhaps, if this year's data turns out well.

Regards, RockRat